Literature DB >> 24189542

Eldecalcitol improves mechanical strength of cortical bones by stimulating the periosteal bone formation in the senescence-accelerated SAM/P6 mice - a comparison with alfacalcidol.

Ayako Shiraishi1, Sadaoki Sakai2, Hitoshi Saito3, Fumiaki Takahashi4.   

Abstract

Eldecalcitol (ELD), a 2β-hydroxypropyloxy derivative of 1α,25(OH)2D3, is a potent inhibitor of bone resorption that has demonstrated a greater effect at reducing the risk of fracture in osteoporotic patients than alfacalcidol (ALF). In the present study, we used the senescence-accelerated mouse strain P6 (SAM/P6), which has low bone mass caused by osteoblast dysfunction, to evaluate the effect of ELD on cortical bone in comparison with ALF. Four-month-old SAM/P6 mice were given either ELD (0.025 or 0.05μg/kg) or ALF (0.2 or 0.4μg/kg) by oral gavage 5 times/week for 6 weeks. Both ELD and ALF increased serum calcium (Ca) in a dose-dependent manner. Serum Ca levels in the ELD 0.05μg/kg group were comparable to those of the ALF 0.2μg/kg group. ELD 0.05μg/kg significantly improved the bone biomechanical properties of the femur compared with the vehicle control group (p<0.001) and the ALF 0.2μg/kg group (p<0.05) evaluated by 3-point bending test. The cortical area of the mid-femur in the ELD 0.05μg/kg group but not the ALF 0.2μg/kg group was significantly higher than those of the vehicle control group (p<0.001). Bone histomorphometry revealed that in the femoral endocortical surface, the suppression of bone resorption parameters (N.Oc/BS) and bone formation parameters (MS/BS) by ELD (0.05μg/kg) was greater than that by ALF (0.2μg/kg). In contrast, in the femoral periosteal surface, ELD 0.05μg/kg significantly increased bone formation parameters (BFR/BS, MS/BS) compared with the vehicle control group (p<0.05, p<0.01, respectively), whereas ALF 0.2μg/kg did not alter these parameters. These results indicate that ELD improved the biomechanical properties of femoral cortical bone not only by inhibiting endocortical bone resorption but also by stimulating the periosteal bone formation in SAM/P6 mice. This article is part of a Special Issue entitled '16th Vitamin D Workshop'.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alfacalcidol; BMD; Bone formation; Eldecalcitol; Osteoporosis

Mesh:

Substances:

Year:  2013        PMID: 24189542     DOI: 10.1016/j.jsbmb.2013.10.024

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  3 in total

1.  Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males.

Authors:  Qian Zhao; Hongzhong Liu; Ji Jiang; Yiwen Wu; Wen Zhong; Lili Li; Kazuhiro Miya; Masaichi Abe; Pei Hu
Journal:  Clin Drug Investig       Date:  2018-10       Impact factor: 3.580

2.  Effects of eldecalcitol on cortical bone response to mechanical loading in rats.

Authors:  Yusuke Yamasaki; Keita Nagira; Mari Osaki; Hideki Nagashima; Hiroshi Hagino
Journal:  BMC Musculoskelet Disord       Date:  2015-06-30       Impact factor: 2.362

3.  Comparative effect of eldecalcitol and alfacalcidol on bone microstructure: A preliminary report of secondary analysis of a prospective trial.

Authors:  Xiaolin Ni; Juan Feng; Yan Jiang; Li Zhang; Wei Yu; Ou Wang; Mei Li; Xiaoping Xing; Toshio Matsumoto; Weibo Xia
Journal:  Osteoporos Sarcopenia       Date:  2021-06-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.